Biogen Eisai's Leqembi Alzheimer's drug rejected by EU regulator
European drug regulators on Friday rejected Leqembi's Alzheimer's treatment Biogen and Eisaicreating another hurdle for companies as they struggle to…
biogen inc
Investors could see evidence in H2 of AI's assistance in drug discovery
As investors look to the future to imagine which industries are ripe to be reshaped and energized by artificial intelligence,…
FDA approval of Eli Lilly's Alzheimer's drug cements our decision not to profit
Each weekday, the CNBC Investment Club with Jim Cramer publishes The Home Stretch, a handy evening update, just in time…
Biogen (BIIB) Earnings Q1 2024
A test tube is seen in front of the Biogen logo in this illustration taken on December 1, 2021. Ruvic…
Eli Lilly (LLY) Says It Can Overcome the Problem of Too Much Demand for High Quality
Eli Lilly's improved guidance stole the show on Tuesday, offsetting mixed first-quarter results and sending shares up nearly 6%. The…
FDA approval of Eli Lilly's Alzheimer's drug delayed
Eli Lilly headquarters in Indianapolis, Indiana, U.S., on Wednesday, May 3, 2023. Shares of Eli Lilly & Co. rose in…
Alzheimer's drug Leqembi launched, nausea Apple Vision Pro
Good afternoon! The launch of the closely watched Alzheimer's drug Leqembi is off to a slow start. Even so, the…
What Eli Lilly Investors Can Learn from the Slow Launch of a Rival Drug
Club holding company Eli Lilly hopes to win approval for its Alzheimer's treatment in the coming weeks, but investors looking…
Biogen (BIIB) earnings in the fourth quarter of 2023
biogen on Tuesday reported fourth-quarter revenue and profit that fell from a year ago as it booked charges related to…
Biogen abandons Alzheimer's drug Aduhelm to focus on Leqembi, others
Biogen headquarters in Cambridge, Massachusetts, on October 24, 2023. vanessa leroy | Bloomberg | fake images biogen on Wednesday said…